MGI Expands Cancer Care Line Via Agreement With Alpharma For Kadian
This article was originally published in The Pink Sheet Daily
Executive Summary
Licensing deal will add cancer pain therapy to Aloxi anti-emetic franchise. Aloxi sales now projected to reach $150 mil. for the year. MGI is discussing “several” additional licensing deals in cancer field.
You may also be interested in...
J&J Duragesic Pediatric Exclusivity Keeps Mylan Fentanyl Patch Off The Market Until January
FDA rejects Mylan's argument linking pediatric exclusivity with the 30-month stay. Mylan says it will sue FDA to restore final approval of its ANDA, which is now deemed tentatively approved.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.